Results from multiple Phase III trials of Icotrokinra in moderate-to-severe plaque psoriasis and a Phase IIb trial in ...
MedPage Today on MSN4d
Topical Therapies for PsoriasisOptimizing use of topical agents begins with defining "mild or moderate." Clinical trials in psoriasis employ objective ...
Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a ...
Verywell Health on MSN12d
How to Tell If You May Have Scalp Psoriasis vs. DandruffMedically reviewed by Susan Bard, MD Psoriasis and dandruff can both trigger itching and flaky scalp skin. Psoriasis is a ...
Two posters presented at the 2025 American Academy of Dermatology Annual Meeting highlighted the importance of improving ...
Five-year data from Phase III trials demonstrated that 67.7% of patients moderate-to-severe plaque psoriasis treated with UCB ...
More than half of patients with fingernail psoriasis achieved complete fingernail clearance after 68 weeks of guselkumab treatment.
News Medical on MSN8d
Targeting SSAT enzyme offers new hope for psoriasis treatmentPsoriasis is one of the most common chronic inflammatory skin diseases, affecting around 250,000 people in Austria.
Verywell Health on MSN11d
Understanding Scalp Psoriasis and How to Treat ItScalp psoriasis can cause crusty patches or scales on the surface of the head. Find details about medicated shampoos, ...
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced ...
La La Anthony is partnering with Amgen to raise awareness and support those struggling with plaque psoriasis. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback